Publication: Pharmacokinetics and safety of PTC596, a novel tubulin-binding agent, in subjects with advanced solid tumors
This research article, published in Clinical Pharmacology in Drug Development, reports the results of a Phase 1 dose-escalation study of PTC596, a novel, orally-administered molecule, being investigated for treatment of solid tumors
Pharmacokinetic data, including bioavailability, absorption, accumulation, and excretion values, for PTC596 given at different doses to human subjects, is provided. Data includes bioavailability and absorption area under the curve
Analysis of adverse effects in patients with a range of solid tumors, along with best overall tumor response to treatment with PTC596 up to 16 weeks, is discussed
Shapiro GI, O’Mara E, Laskin OL, et al.Clin Pharmacol Drug Dev. 2021. Published online ahead of print
Once registered, you will be provided the DOI and PubMed links for this publication.
Register now to unlock the content
Register now to access the content on this page
If not, register below
MED-ALL-DIPG-2100031 | October 2021
Sign in or register to access exclusive content on this site
Some cookies are essential, others help us improve your experience by providing insights into how the website is used. Select one or more of the cookie types listed below, and then save your preferences. Refer to our Cookies Statement for more information.
Performance cookies, which help us measure the website’s performance and improve your experience. In using performance cookies we do not store any personal data, and only use the information collected through these cookies in aggregated and anonymised form.